Tesamorelin has randomized human trial evidence for reducing visceral fat in specific HIV-associated abdominal fat accumulation. This does not establish its effectiveness or safety for physique use in otherwise healthy people.
Key points
- The studied population had a defined medical condition and clinician monitoring.
- Trials found reductions in visceral and, in a separate study, liver fat.
- Growth-hormone and IGF-1 effects require consideration beyond changes on a scale.
What the literature shows
Falutz and colleagues compared tesamorelin with placebo in adults with HIV-associated abdominal fat accumulation and observed reduced visceral adipose tissue. This was not a trial of healthy athletes or general weight loss.
Stanley and colleagues investigated visceral and liver fat in a separate randomized clinical trial in a similar clinical context. These endpoints do not establish changes in strength or athletic performance.
What remains unknown
- Benefits and risks in people without the trial condition are uncertain.
- Long-term outcomes after discontinuation and across differing health histories cannot be inferred from short trials.
Safety and monitoring implications
- A discussion of glucose status and growth-factor effects belongs with medical supervision rather than self-monitoring alone.
- Avoid translating trial results into unsupervised dosing or a claim of targeted cosmetic fat loss.
Cited literature
- 1.Falutz J, Potvin D, Mamputu JC, et al. (2010). Effects of tesamorelin, a growth hormone–releasing factor, in HIV-infected patients with abdominal fat accumulation. JAIDS. Find on PubMed
- 2.Stanley TL, Feldpausch MN, Oh J, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying Tesamorelin in Australia: what to check first
APEDRA does not sell Tesamorelin or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.